Evidence map›Paper›PMID 26036801›Full record

ArticleBlood2015

Chronic transfusion therapy improves but does not normalize systemic and pulmonary vasculopathy in sickle cell disease.

Jon A Detterich, Roberta M Kato, Miklos Rabai, Herbert J Meiselman, Thomas D Coates, John C Wood

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Blood, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05469828 (Crizanlizumab Improves Tissue Oxygen Supply Demand Matching in Patients With Sickle Cell Anemia), which is not on this map. Cited by 36 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 2 pooled it
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05469828 phase1 / phase2not yet recruitingnot on this mapstarted 2024, after this paper: background citation

Crizanlizumab Improves Tissue Oxygen Supply Demand Matching in Patients With Sickle Cell Anemia

TypeinterventionalSponsorChildren's Hospital Los AngelesRan2024 to 2029Enrolled30ConditionsSickle Cell DiseaseArmsCrizanlizumab, control
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. The Cardiopulmonary Complications of Sickle Cell Disease.Hematology/oncology clinics of North America · 2022
    Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Jon A DetterichDivision of Cardiology, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA; Department of Physiology and Biophysics, University of Southern California Keck School of Medicine, Los Angeles, CA;ORCID http://orcid.org/0000-0002-2086-9569
Roberta M KatoDivision of Pediatric Pulmonology, Children's Hospital Los Angeles, Los Angeles, CA;
Miklos RabaiDepartment of Medicine, University of Pecs, Pecs, Hungary; and.
Herbert J MeiselmanDepartment of Physiology and Biophysics, University of Southern California Keck School of Medicine, Los Angeles, CA;
Thomas D CoatesDivision of Hematology, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA.
John C WoodDivision of Cardiology, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA;ORCID http://orcid.org/0000-0003-0996-3439
University of Southern California · USChildren's Hospital of Los Angeles · USUniversity of Pecs · HU

Funding

ZOPOLRESTAT IN NORMOTENSIVE, TYPE 1 DIA WITH INCIPIENT NEPHROPATHYM01RR000043 · NCRR · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ZAIA, JOHN A · 1985 to 2010
$76.4M
Neuromodulatory Mechanisms and Regional Autonomic Dysregulation in the Development of Pain in Sickle Cell Disease PatientsU01HL117718 · NHLBI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI COATES, THOMAS DUANE, KHOO, MICHAEL C K · 2013 to 2017
$9.6M
Childrens Hospital Los Angeles Child Health Research Development AwardK12HD052954 · NICHD · CHILDREN'S HOSPITAL OF LOS ANGELES · PI WILLIAMS, ROBERTA GAY · 2006 to 2017
$4.0M
Sickle Cell Scholar ComponentU54HL090511 · NHLBI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI COATES, THOMAS DUANE · 2008 to 2011
$2.6M
Iron-mediated vascular disease in sickle cell disease.RC1HL099412 · NHLBI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI WOOD, JOHN C · 2009 to 2010
$995k
Erythrocyte Nitric Oxide Links Rheology and Vasculopathy in Sickle Cell DiseaseK23HL119627 · NHLBI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI DETTERICH, JON A · 2014 to 2016
$497k
NCRR NIH HHS M01 RR000043NCRR NIH HHS RR00043-43NHLBI NIH HHS 1 K23 HL 119627-01A1NHLBI NIH HHS 1 U54 HL090511-01NHLBI NIH HHS 1U54 HL117718NHLBI NIH HHS 5 RC1 HL099412-01NHLBI NIH HHS K23 HL119627NHLBI NIH HHS RC1 HL099412NHLBI NIH HHS U01 HL117718NHLBI NIH HHS U54 HL090511NICHD NIH HHS 2 K12 HD 52954-6 A1NICHD NIH HHS K12 HD052954
6 · The paper itself

Abstract

Tricuspid regurgitant (TR) jet velocity and its relationship to pulmonary hypertension has been controversial in sickle cell disease (SCD). Plasma free hemoglobin is elevated in SCD patients and acutely impairs systemic vascular reactivity. We postulated that plasma free hemoglobin would be negatively associated with both systemic and pulmonary endothelial function, assessed by flow-mediated dilation (FMD) of the brachial artery and TR jet velocity, respectively. Whole blood viscosity, plasma free hemoglobin, TR jet, and FMD were measured in chronically transfused SCD pre- and posttransfusion (N = 25), in nontransfused SCD (N = 26), and in ethnicity-matched control subjects (N = 10). We found increased TR jet velocity and decreased FMD in nontransfused SCD patients compared with the other 2 groups. TR jet velocity was inversely correlated with FMD. There was a striking nonlinear relationship between plasma free hemoglobin and both TR jet velocity and FMD. A single transfusion in the chronically transfused cohort improved FMD. In our patient sample, TR jet velocity and FMD were most strongly associated with plasma free hemoglobin and transfusion status (transfusions being protective), and thus consistent with the hypothesis that intravascular hemolysis and increased endogenous erythropoiesis damage vascular endothelia.

Indexed as

Blood TransfusionAdolescentAdultAnemia, Sickle CellBlood Flow VelocityBrachial ArteryCase-Control StudiesEchocardiographyEndothelium, VascularFemaleHeartHemoglobinsHemolysisHumansHypertension, PulmonaryLungHemoglobins

Identifiers

PMID26036801
PMCPMC4528063
OpenAlexW1192008708

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.